Vermillion takes on two senior heads
pharmafile | December 15, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â david schreiber, vermillion, veronica jordanÂ
US drug development firm Vermillion has appointed Veronica Jordan and David Schreiber to the company’s board of directors.
Dr Veronica Jordan (pictured) is an accomplished entrepreneur and as an advisor to life science and healthcare companies, takes much business experience to the Austin, Texas-based firm.
From 2001-2006 she was chief executive and a director of Medelle Corporation, a private, venture capital funded medical device company in women’s health. Prior to that she served for fourteen years in various executive positions at PAREXEL.
Jordan has held leadership roles at Biogen Idec and managed an R&D department for Baxter International. Jordan currently serves on the board of Albany Molecular Research.
Schreiber has more than 30 years of corporate and consulting experience in the healthcare industry – particularly in the area of corporate finance, operations, and mergers and acquisitions.
Since 2004, he has provided consulting services on a wide variety of healthcare projects. In addition, he currently supports M&A due diligence research in the lab industry for Warburg Pincus.
His corporate experience includes serving as senior VP and chief financial officer of DIANON Systems from 1996 until its sale to LabCorp in 2003. He has also served in management roles at Corning Clinical Laboratories and Unilab.
Jim LaFrance who is the chairman, president, and chief executive of Vermillion says: “I am tremendously pleased to announce the appointments of Veronica and David to our board of directors. Each of them brings vast experience in key areas of operations, as well as broad and deep understanding of the healthcare industry and the growing need for predictive medicine.”
